Conditions: Dyslipidemia
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 220
Healthy volunteers: yes

Brief summary:
This study will evaluate:

1. the bioequivalence of simvastatin and simvastatin acid following dose of simvastatin (ZOCOR™) given together with one tablet of MK0524A or as a component of the triple combination tablet MK0524B.
2. the bioequivalence of laropiprant and ER niacin when administered as the triple combination tablet MK0524B or as the double combination tablet MK0524A given together with simvastatin.

Detailed description:

Arms:
arm 1: Period 1: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).

Period 2: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets. arm 2: Period 1: 1 tablet of simvastatin 20 mg (Zocor™) and 1 tablet of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) as separate tablets.

Period 2: 1 tablet of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg).

Interventions: intervention 1: MK0524B (ER niacin (+) laropiprant (+) simvastatin) intervention 2: MK0524A (ER niacin + laropiprant) intervention 3: Simvastatin
Intervention descriptions: intervention 1: Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods. intervention 2: Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods. intervention 3: Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.

Protocol document: